A final milestone has been passed by the European Regulation for a waiver that will allow firms to manufacture generics and biosimilars during the term of supplementary protection certificates (SPCs), after it was formally adopted by the European Council.
The Council’s move comes just under a month after Europe’s off-patent industry celebrated the European Parliament’s decision to approve the Regulation by a significant majority, with 572 members of parliament voting in favor